AACE convened a conference to review factors associated with cancer development in people with obesity and diabetes and to discuss the possible cancer risk of antihyperglycemic medications.

Recent reports of diabetic ketoacidosis (DKA) occur-ring in conjunction with sodium glucose-cotransporter 2 (SGLT-2) inhibitor therapy have raised concerns that these agents may increase the risk of DKA, especially among patients

Among the more than 20 million Americans whohave diabetes, approximately 30% of the cases are undi-agnosed (1).

Evidence-based medicine has generated many philosophical and pragmatic challenges to clinical care. Chief among these challenges is how to deliver culturally appropriate individualized endocrine care while adhering to evidence-based guidelines and algorithms developed for large heterogeneous populations.
Since its inception, the American Association of Clinical Endocrinologists (AACE) has advocated for the finest in endocrine education and state-of-the-art health-care delivery without regard to race, ethnicity, gender, age, country of origin, economic status, lifestyle, sexual orientation or domestic living arrangements.
A position statement by the American Association of Clinical Endocrinologists